Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Diego Perez Diez
Prof. Josep Brugada
ARVD is an important cause of malignant ventricular arrhythmias among apparently healthy young subjects. Management involves the suppression of malignant arrhythmias with pharmacologic drugs or placement of an ICD as most effective treatments to prevent sudden cardiac death. Life long monitoring of patients with ARVD by the primary care physician and cardiologist is recommended.
ARVD is a disease of the heart muscle associated with ventricular arrhythmias and sudden death. It is characterised by structural and functional abnormalities of the right ventricle caused by the replacement of the myocardium by fatty and fibrous tissue. The sites of involvement of anatomic abnormalities are found in the so-called triangle of dysplasia (the right ventricular subtricuspid areas, the apex and the infundibulum)(4). Arrythmogenic right ventricular dysplasia (ARVD) is an inherited disease, typically inherited as an autosomal dominant trait with variable penetrance and incomplete expression(1). There is an autosomal recessive variant associated with palmoplantar keratosis and wally hair named Naxos disease.
The prevalence in the general population is approximately from 1:2500 to 1:5000 Nevertheless, itis dependent on geographic circumstances, for example in certain regions of Italy (Padua, Venice) and Greece (island of Naxos), the prevalence is increased(2). It accounts for 5% to 10% of unexplained sudden cardiac deaths in individuals under65 years(3). It occurs in young adults with a male to female ratio of 2,7/1. After hypertrophic heart disease, it is the number one cause of sudden cardiac death in young people.
Diagnosis of ARVD is often difficult because there is no single test. Diagnosis is based on the presence of structural, histological, electrocardiographic and genetic factors according to the 1994 Task Force Report by McKenna et al (5) (table 1) and a modification of the Task Force by Homid et al (6) (table 2) to increase the diagnostic sensitivity of first degree family members for early detection of the disease.
A) Clinical history First of all, we’ll start with the easier tool, that is, clinical history. Clinical presentation varies from asymptomatic forms to palpitations, fatigue, syncope or even cardiac arrest usually during exercise. These symptoms are due to ventricular ectopic beats, sustained ventricular tachycardia of left bundle branch block configuration or right ventricular failure(4).
We can identify four stages in the natural history of this disease(7): a) the early or silent phase, it is a subclinical phase with concealed structural abnormalities b) the unstable phase with electrical disorder c) the right ventricular failure phase d) the final phase with progressive biventricular failure, mimicking dilated cardiomyopathy
B) Diagnostic test 1.- Electrocardiogram
There are several ECG features in the criteria diagnosis of ARVD: a) T wave inversions in V1 through V3 (minor diagnostic criterion, but one of most common ECG abnormality present in 85% of patients (8) b) QRS duration = 110 ms in V1 through V3 c) Epsilon wave (electric potentials after the end of the QRS complex). It is a major diagnostic criterion found in up to 30% of cases of ARVD.
Other ECG markers of ARVD have been reported: QRS and QT dispersion, parietal block defined as a QRS duration in leads V1 through V3 that exceeds the QRS duration in lead V6 by > 25 ms, a prolonged S-wave upstroke in V1 through V3 = 55 ms (it was seen as the most prevalent ECG feature in 95% of ARVD8
2.- Myocardial imaging
It is the non-invasive imaging technique most widely used but it is not always the optimal imaging technique in obese patients and in patients with pulmonary emphysema. Echocardiography is the initial diagnostic approach in patients suspected of having ARVD. Principal findings are (9):
- right ventricular dilation and hypokinesia - isolated dilatation of the right ventricular outflow tract - increased reflectivity of the moderator band - end-diastolic aneurysms - akinesis-dyskinesis of the inferobasal segment and the right ventricular apex - prominent apical trabeculae
2.2 Right ventricular contrast angiography
This technique is considered the reference standard for the diagnosis of ARVD (10). It consists of akinetic-dyskinetic areas localised in the anatomic triangle of dysplasia. However, due to an invasive technique, X-ray exposure, the interobserver variability, this method is not widely used (9).
2.3 Computed tomography
Computed tomography is capable of diagnosing patients with ARVD. Dery et al11, were the first to demonstrate a dilated hypokinetic right ventricle in a patient with ARVD. Findings of ARVD on electron-beam computed tomography are7:
- the presence of epicardial fat or intramyocardial fat deposits - conspicuous trabeculations with low attenuation - dilated hypokinetic right ventricle - scalloped appearance of the right ventricular wall
Currently, computed tomography is not the optional imaging modality for initial screening due to high radiation burden.
2.4 Cardiovascular magnetic resonance imaging
Magnetic resonance (MR) is an excellent tool for visualising the right ventricle, it allows a three-dimensional evaluation of ventricular anatomy, volumes and when compared against other techniques it can better recognise the replacement of myocardial fatty and fibrofatty tissue, although fatty infiltration of the right ventricle is not exclusive of ARVD, as it occurs in more than 50% of normal hearts in elderly people. However the presence of transmural fatty replacement or diffuse thinning of the right ventricle myocardium should be considered to be a major criterion for the diagnosis of ARVD.
MR can also be used to assess both systolic and diastolic function. Several studies have addressed the presence of right ventricular diastolic dysfunction as an early marker of the disease (12) The typical criteria that can be demonstrated with MR are: - presence of high-signal intensity areas indicating the substitution of myocardium by fat (major criterion) - fibrofatty replacement which leads to diffuse thinning of the right ventricular myocardium (major criterion) - aneurysm of the right ventricle and right ventricular outflow tract (major criterion) - dilatation of the right ventricle and right ventricular outflow tract (when severe, major criterion; when mild, minor criterion) - regional contraction abnormalities (minor criterion) - global systolic dysfunction (major criterion) and global diastolic dysfunction (minor criterion)
Cardiovascular magnetic resonance imaging provides important anatomic, morphologic, functional and flow-dynamic criteria for diagnosing ARVD although the diagnosis of ARVD must be made based on Task Force criteria and not on structural abnormalities only.
2.5 Endomyocardial biopsy
Histological diagnosis is definitive, however endomyocardial biopsy is controversial because of the segmental nature of the disease and the samples are usually obtained from the septum (13). Complications can occur such as tamponade and perforation.
Before treatment, we have to know predictors of mortality and risk stratification. The study of Hulot et al (14) found that at least 1 episode of left bundle-branch block ventricular tachycardia, clinical signs of right ventricular failure and left ventricular dysfunction were associated with cardiovascular deaths. The problem is that the appearance of sudden death is not related to disease progression and sudden death could be the first manifestation of the disease.
1.- Antiarrhythmic drugs
Antiarrhythmic drugs are the initial and most commonly used therapy. Beta-adrenergic blocking agents are recommended to reduce adrenergic stimulated arrhythmia. The most successful drug is sotalol. Sotalol was more effective than beta-blocking agents or amiodarone in patients with inducible and non inducible ventricular tachycardia (VT) administered in dosages ranging from 320 to 480 mg/day (sotalol prevented VT during programmed ventricular stimulation in 68% whereas amiodarone 26% and class Ia and Ib 5,6% and class Ic only in 3% of the patients) (15).
2.- Catheter ablation
Radiofrequency ablation (RF) is used in cases of drug refractory/intolerance or incessant ventricular tachycardia. The goal of RF ablation is to eliminate conduction pathways. It is associated with complete success in only 30 to 65% of cases. Due to the progressive and diffuse nature of the disease, it isdifficult to abolish multiple arrhythmogenic foci16. The patologic substrate is recorded during electrophysiologic study as a low amplitude, fractionated endocardial signal reflecting diminished local endocardial conduction velocity7.
3.- Implantable cardioverter-defibrillator therapy
Patients considered at high risk for sudden cardiac death should receive an implantable cardioverter-defibrillator (ICD). They are those who 1) have been resuscitated from cardiac arrest with a history of syncope, 2) have threatening arrhythmias that are not completely suppressed by antiarrhythmic drug therapy and 3) with a family history of cardiac arrest in first degree relatives (primary prevention). ICDs work by providing antitachycardia pacing and defibrillation shocks when arrhythmias occur. ICD therapy is feasible and safe in patients with ARVD with a low incidence of short term and long term complications. This tool has an important role in the treatment of ventricular arrhythmias, more than three quarters of ARVD patients received appropriate ICD therapy during an average of 3,5 years of follow up (17) However, there can be complications of ICD therapy as result of the replacement of right ventricle myocardium with fat and fibrotic tissue. These include perforation caused by thinning of the right ventricle wall, difficulty in lead placement to inadequate R wave amplitudes or high pacing thresholds, inadequate sensing or pacing during follow-up resulting from disease progression and failure to terminate ventricular arrhythmias to rising defibrillation thresholds (18).
4.- Cardiac failure treatment
When right ventricular or biventricular failure appear, treatment consists of the current therapy for heart failure including diuretics, beta blocking agents, angiotensin-converting enzyme inhibitors and anticoagulants. Curative therapy in case of refractory congestive heart failure and/or arrhythmias is cardiac transplantation.
Figure 1. Recording a post-excitation epsilon wave (arrows) in right precordial leads.
Figure 2. 12 lead ECG recording of VT with left bundle branch block morphology
Table 1. Criteria for diagnosis of right ventricular dysplasiaI Global and/or regional dysfunction and structural alterations
II Tissue characterisation of walls
III Repolarisation abnormalities
IV Depolarisation/conduction abnormalities
VI Family history
Table 2. Proposed modification of Task Force for the diagnosis of familial ARVD
ARVD in a first-degree relative plus one of the following:
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology
1.- Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2001;38:1773-81. 2.- Thiene G, Basso C. Arrhythmogenic right ventricular cardiomyopathy: an update. Cardiovasc Pathol 2001;10:109-117.3.- Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003;108:3000-3005.4.- Anderson EL. Arrhythmogenic right ventricular dysplasia. Am Fam Physician 2006;73:1391-8. 5.- McKenna WJ, Thiene G, Nava A, et al. Diagnosis of Arrhythmogenic right ventricular dysplasia/cardiomyopathy: task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71:215-8. 6.- Hamid MS, Norman M, Quraishi A, Firoozi S, Thaman R, Gimeno JR, Sachdev B, Rowland E, Elliott PM, McKenna WJ. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002;40:1445-1450. 7.- Kies P, Bootsma M, Bax J, Schalij MJ, Van der Wall EE. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis and treatment. Heart Rhythm 2006;3:225-234. 8.- Nasir K, Bomma C, Tandri H, Roguin A, Dalal D, Prakasa K, Tichnell C, James C, Jspevak P, Marcus F, Calkins H. Electrocardiographic features of Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation 2004;110:1527-1534. 9.- Tomé Esteban MT, García Pinilla JM, McKenna WJ. Update in Arrhythmogenic right ventricular cardiomyopathy:genetic, clinical presentation and risk stratification. Rev Esp Cardiol 2004;57(8):757-67. 10.- Fontaine G, fontaliran F, Hebert JL, Chemla D, Zenati O, Lecarpentier Y, et al. Arrhythmogenic right ventricular dysplasia. Annu Rev Med 1999;50:17-35. 11.- Dery R, Lipton MJ, Garrett JS, Abbott J, Higgins CB, Scheinman MM. Cine-computed tomography of arrhythmogenic right ventricular dysplasia. J Comput Assist Tomogr 1986;10:120-123. 12.- Kayser HWM, van der Wall EE, Sivananthan MU, plein S, Bloomer TN, de roos A. Diagnosis of arrhythmogenic right ventricular dysplasia: A review. Radiographics 2002;22:639-650. 13.- Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet Journal of Rare Diseases 2007;2:45. 14.- Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2004;110:1879-1884. 15.- Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992;86:29-37. 16.- Fontaine G, Tonet J, Gallais Y, Lascault G, Hidden-Lucet F, Aouate P, Halimi F, Poulain F, Johnson N, Charfeddine H, Frank R. Ventricular tachycardia ablation in arrhythmogenic right ventricular dysplasia; a 16 year experience. Curr Cardiol Rep 2000;2:498-506. 17.- Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, Rutberg J, Crosson J, Spevak PJ, Berger RD, Halperin HR, Calkins H. Implantable Cardioverter-defibrillators in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Am Coll Cardiol 2004;43:1843-52. 18.- Ellenbogen KA, Wood MA, Shepard RK et al. Detection and management of an implantable cardioverter defibrillation lead failure: incidence and clinical implications. J Am Coll Cardiol 2003;41:73-80.
Diego Pérez Díez, M.D., Josep Brugada , M.D., Ph.D. Arrhythmia Section, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Spain
© 2017 European Society of Cardiology. All rights reserved